Volume 10, Issue 08, August 2024,
Publish Date: 12-08-2024
Doi https://doi.org/10.55640/ijmsdh-10-08-03

International Journal of Medical Science and Dental Health (Open Access)

FIGHTING FATTY LIVER DISEASE: PATHOGENESIS AND THERAPEUTIC APPROACHES

Athraa fouad kadhium

Middle technical university, Technical medical Institute _ Baghdad

ABSTRACT

FLD is a burgeoning international ailment closely associated with the increasing rates of obesity, type II diabetes mellitus and physical inactivity. This review focuses on the various aspects of FLD pathophysiology including genetic susceptibility, metabolic disturbances, inflammation, oxidative stress, and environmental factors. Diagnostic tests can be simple and non-invasive such as imaging and biomarkers and can be relatively invasive, such as liver biopsies. Currently the treatment focus is made on drug and surgical interventions with lifestyle changes, and besides, gene and stem cell therapies remain an experimental method with fewer evidences. The article points to the problems of patient compliance, adequate diagnostics, and effectiveness of the treatment, the necessity of working on the concept of individualized medicine, new therapeutic strategies, and prevention. A statically and working knowledge and a combination and complex strategy are required to approach and decrease the burden of FLD worldwide.

INTRODUCTION

NASH or non-alcoholic steatohepatitis has become a major health problem in the modern world where millions of people experience the symptoms of hepatic steatosis. This is the medical condition where the fat content of liver is elevated to a pathological level; its complications include fibrosis, cirrhosis and in some occasions, hepatocellar carcinoma. Fatty liver disease is seen more commonly in the current generation, especially associated with obesity, type 2 diabetes, and metabolic syndrome; hence, calls for an enhanced appraisal of the mechanisms of its development and treatment measures [1, 2].

As a result, knowing the factors that cause the formation of fatty liver and its further progression has great potential to discover future treatments. The pathophysiology of this disease is not very clear, but it might be propped up by familial factors, metabolic disturbances, inflammation, stress by free radicals, and factors in the environment. In addition, there are new developments in the diagnostic methods to diagnose and manage FLD more efficiently thus opening up new therapeutic strategies [3, 4].

The present management of FLD therefore involves the adoption of lifestyle changes, the use of drugs and chemicals and surgery. However, the conservative measures of weight loss and exercise reform are still the mainstay of treatment, medical and surgical interventions offer the next steps for patients with more extensive disease or who have not achieved optimum results with lifestyle modifications alone.

Considering that new approaches are under development, gene therapy and stem cell therapy are believed to be the future of the treatment methods [5, 6].

To accomplish this goal, this review will give a brief description on which factors contribute to the development and progression of fatty liver disease and a detailed comprehensive analysis of the available and investigational treatment strategies for the condition. Through the presentation of information that may help elucidate this condition and specify the directions for future investigations, the authors' intent is to fuel further research and treatment of fatty liver disease and enhance patients' quality of life.

Pathogenesis of Fatty Liver Disease

FLD patogenesis and disease progression are determined by the interdependent genetic, metabolic, inflammatory, and environmental changes. This is quite essential for the formulation of treatment and prevention mechanisms [7].

Genetic Factors

Gene Mutations and Polymorphisms

Family history is another important determinant of the likelihood of getting FLD since certain diseases run in families. Several polymorphisms of especially PNPLA3 and TM6SF2 genes have been associated with steatosis, which is propensity to store fat in liver cells. These polymorphisms can affect lipid profile, inflammation and fibrosis [8-10].

Hereditary Patterns

Research going to the family homogeneity has confirmed that FLD can be hereditary. Genetic studies for FLD will assist in early diagnosis and individualized management plans once definite genetic sites have been predicted [11, 12].

Metabolic Imbalances

Insulin Resistance

In FLD, insulin action on the liver is reduced leading to insulin resistance. It promotes lipogenesis in adipose tissue and indirectly the levels of free fatty acids are raised in the circulating blood stream. These fatty acids are incorporated into the liver, thus are implicated in the development of hepatic steatosis [13, 14].

Lipid Metabolism Dysregulation

In addition to this, the disrupted lipid metabolism where there is increased de novo lipogenesis as well as compromised fatty acid oxidation add to the problematic fat deposition in the liver. The dysregulation in these pathways are regulated by enzymes and transcription factors inclusive of SREBP-1c and PPAR-α [15, 16].

Inflammatory Processes

Role of Cytokines and Chemokines

Another aspect revealed in FLD subjects is subclinical low-grade inflammation. Adipokines such as TNF-α and IL-6 as well as chemokines exert inflammogenic impact on liver by stimulating immune cells activity and direct hepatocyte damage. To that, these molecules will induce signal transduction that leads to the processes of hepatocyte apoptosis and fibrosis [17, 18].

Chronic Inflammation and Liver Damage

Chronic inflammation is a major factor in the development of progressive hepatic pathology, fibrosis and cirrhosis included. Kupffer cells and hepatic stellate cells are the primary cells implicated in this inflammatory response; the latter is involved in the synthesis of extracellular matrix proteins in fibrotic manifestations [19, 20].

Oxidative Stress

Mechanisms of Oxidative Damage

Oxidative stress is defined as a condition wherein the amount and activity of ROS exceed the body's ability to detoxify or neutralize them. High amount of ROS can harm cellular structures such as lipids, proteins and DNA, causing hepatocyte dysfunction and eventually, apoptosis [21].

Antioxidant Defense Systems

The antioxidant defenses in the liver like glutathione and superoxide dismutase are usually altered in FLD. Aging, therefore, may be characterized by decreased abilities to prevent and repair oxidative damage or target more grim treatments toward this goal; however, augmenting these defenses through pharmacological or dietary means might be effective [22].

Environmental and Lifestyle Factors

Diet and Nutrition

A variety of aspects, which relates to one's diet, contribute to the development of FLD. Saturated fatty acid consumption, refined carbohydrates and fructose are some of the aspects that have been said to increase the risk. Whereas, fats contained in fruits, vegetables, and omega 3 fatty acid contained foods emanate protection [23, 24].

Alcohol Consumption

NAFLD is a condition characterized by elevated levels of liver fat, without substantial alcohol use; however, alcohol has an adverse effect on NAFLD progression by increasing liver fat and inflammation. It is also important to note that even moderate drinking decreases the prognosis of NAFLD [25].

Physical Activity

Physical inactivity is a risk factor for FLD. Regular exercise improves insulin sensitivity, supports weight loss, and enhances lipid metabolism, thereby reducing liver fat content.

Table 1 *(Summary of Pathogenesis of Fatty Liver Disease.)*

Category	Subcategory	Details

Genetic Factors	Gene Mutations and Polymorphisms	- PNPLA3 and TM6SF2 gene mutations - Influence on lipid metabolism and inflammation
	Hereditary Patterns	- Familial aggregation - Use of genetic markers for early diagnosis
Metabolic Imbalances	Insulin Resistance	- Increased lipolysis and free fatty acid levels - Contribution to hepatic steatosis
	Lipid Metabolism Dysregulation	- Increased de novo lipogenesis - Impaired fatty acid oxidation - Role of SREBP-1c and PPAR-α
Inflammatory Processes	Role of Cytokines and Chemokines	- Pro-inflammatory cytokines (TNF-α, IL-6) - Activation of signaling pathways leading to liver damage
	Chronic Inflammation and Liver Damage	- Involvement of Kupffer cells and hepatic stellate cells - Production of extracellular matrix proteins
Oxidative Stress	Mechanisms of Oxidative Damage	- Imbalance between ROS production and antioxidant defenses - Damage to lipids, proteins, and DNA
	Antioxidant Defense Systems	- Overwhelmed glutathione and superoxide dismutase - Potential for pharmacological or dietary enhancement
Environmental and Lifestyle Factors	Diet and Nutrition	- High intake of saturated fats, refined carbs, fructose - Protective effects of fruits, vegetables, omega-3 fatty acids
	Alcohol Consumption	- Exacerbation of liver fat accumulation and inflammation - Impact on NAFLD prognosis
	Physical Activity	- Risk factor for FLD - Benefits of regular exercise on insulin sensitivity, weight loss, lipid metabolism

Diagnostic Approaches

Accurate diagnosis of fatty liver disease (FLD) is essential for effective management and treatment. Diagnostic methods range from non-invasive techniques to more invasive procedures, each offering unique insights into the presence and severity of the disease.

Non-Invasive Techniques

Imaging Modalities

- **Ultrasound [26]:**
  - Widely used due to its cost-effectiveness and accessibility.
  - Can detect increased liver echogenicity, indicative of fat accumulation.
  - Limitations include operator dependency and reduced sensitivity in obese patients.
- **Magnetic Resonance Imaging (MRI) [27]:**
  - Provides more accurate quantification of liver fat content compared to ultrasound.
  - Magnetic Resonance Spectroscopy (MRS) can measure hepatic triglyceride content.
  - More expensive and less widely available than ultrasound.
- **Computed Tomography (CT) [28]:**
  - Can identify steatosis based on liver attenuation values.
  - Exposure to ionizing radiation is a significant drawback.

Biomarkers and Blood Tests

- Liver Function Tests (LFTs) [29]:
  - Elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) can indicate liver damage.
  - Not specific for FLD, as these enzymes can be elevated in other liver conditions.
- **Serum Biomarkers [30]:**
  - Markers such as cytokeratin-18 fragments can indicate hepatocyte apoptosis.
  - Fibrosis scores like FIB-4 and NAFLD fibrosis score (NFS) can help assess liver fibrosis.

Invasive Techniques

Liver Biopsy

- **Histopathological Examination [31]:**
  - Gold standard for diagnosing and staging FLD.
  - Can differentiate between simple steatosis and steatohepatitis (NASH).
  - Risks include pain, bleeding, and sampling variability.

Emerging Techniques

- Elastography [32]:
  - Measures liver stiffness as a proxy for fibrosis.
  - Techniques include Transient Elastography (FibroScan) and Magnetic Resonance Elastography (MRE).
  - Non-invasive and increasingly used in clinical practice.

Table 2 *(Diagnostic Approaches for Fatty Liver Disease.)*

Category	Subcategory	Details
Non-Invasive Techniques	Imaging Modalities	
	- Ultrasound	- Cost-effective and accessible - Detects increased liver echogenicity - Operator dependent, less sensitive in obese patients
	- Magnetic Resonance Imaging (MRI)	- Accurate quantification of liver fat - MRS measures hepatic triglyceride content - Expensive and less widely available
	- Computed Tomography (CT)	- Identifies steatosis based on liver attenuation values - Exposure to ionizing radiation
	Biomarkers and Blood Tests	
	- Liver Function Tests (LFTs)	- Elevated ALT and AST indicate liver damage - Not specific to FLD
	- Serum Biomarkers	- Cytokeratin-18 fragments indicate hepatocyte apoptosis - Fibrosis scores (FIB-4, NFS) assess fibrosis
Invasive Techniques	Liver Biopsy	
	- Histopathological Examination	- Gold standard for diagnosing and staging FLD - Differentiates between simple steatosis and NASH - Risks: pain, bleeding, sampling variability
Emerging Techniques	Elastography	
	- Transient Elastography (FibroScan)	- Measures liver stiffness as a proxy for fibrosis - Non-invasive and increasingly used
	- Magnetic Resonance Elastography (MRE)	- Advanced technique for measuring liver stiffness - Provides detailed imaging

Current Therapeutic Approaches

The management of fatty liver disease (FLD) involves a combination of lifestyle interventions, pharmacological treatments, and, in some cases, surgical procedures. These approaches aim to reduce liver fat, improve liver function, and prevent progression to more severe liver damage.

Lifestyle Modifications

Dietary Interventions [33, 34]

- Caloric Restriction: Reducing caloric intake can lead to weight loss and decrease liver fat.
- Macronutrient Composition: Diets low in carbohydrates and high in healthy fats (e.g., Mediterranean diet) have shown beneficial effects.
- Avoidance of Fructose and Saturated Fats: Limiting intake of sugary beverages and processed foods can reduce liver fat accumulation.

Exercise Programs [35]

- Aerobic Exercise: Regular aerobic exercise (e.g., walking, jogging, cycling) improves insulin sensitivity and reduces liver fat.
- Resistance Training: Strength training exercises can also contribute to weight loss and metabolic improvements.

Pharmacological Treatments

Insulin Sensitizers [36]

- Metformin: Commonly used in type 2 diabetes; has shown some benefit in reducing liver fat but not universally recommended for FLD.
- Thiazolidinediones (e.g., Pioglitazone): Improve insulin sensitivity and have shown efficacy in reducing liver fat and inflammation.

Lipid-Lowering Agents [37]

- Statins: Primarily used for managing hyperlipidemia; may have secondary benefits in reducing liver fat.
- Omega-3 Fatty Acids: Supplements can reduce triglyceride levels and have shown some efficacy in reducing liver steatosis.

Antioxidants and Anti-inflammatory Drugs [38]

- Vitamin E: An antioxidant that has shown benefit in non-diabetic patients with FLD.
- Pentoxifylline: Used for its anti-inflammatory properties; may reduce liver inflammation and fibrosis.

Surgical Interventions

Bariatric Surgery [39]

- Types of Procedures: Includes gastric bypass, sleeve gastrectomy, and adjustable gastric banding.
- Effects on FLD: Significant weight loss post-surgery can lead to substantial improvements in liver steatosis, inflammation, and fibrosis.

Liver Transplantation [40]

- Indications: Considered for patients with end-stage liver disease due to FLD who do not respond to other treatments.
- Outcomes: Post-transplant outcomes are generally favorable, but recurrence of FLD is possible if underlying risk factors persist.

Emerging Therapies

Gene Therapy [41]

- Approach: Targets specific genetic mutations or pathways involved in FLD.
- Current Status: Experimental stage with ongoing clinical trials.

Stem Cell Therapy [42]

- Approach: Uses stem cells to repair damaged liver tissue and improve liver function.
- Current Status: Early-stage research with promising preliminary results.

Table 3 *(Current Therapeutic Approaches for Fatty Liver Disease.)*

Category	Subcategory	Details
Lifestyle Modifications	Dietary Interventions	- **Caloric Restriction:** Reduces caloric intake to decrease liver fat - **Macronutrient Composition:** Low-carb, high-healthy fat diets (e.g., Mediterranean diet) - **Avoidance:** Limit fructose and saturated fats
	Exercise Programs	- **Aerobic Exercise:** Improves insulin sensitivity, reduces liver fat (e.g., walking, jogging) - **Resistance Training:** Contributes to weight loss and metabolic improvements
Pharmacological Treatments	Insulin Sensitizers	- **Metformin:** Benefits in reducing liver fat, not universally recommended - **Thiazolidinediones (e.g., Pioglitazone):** Improve insulin sensitivity, reduce liver fat and inflammation
	Lipid-Lowering Agents	- **Statins:** Manage hyperlipidemia, secondary benefits in reducing liver fat - **Omega-3 Fatty Acids:** Reduce triglyceride levels, reduce liver steatosis
	Antioxidants and Anti-inflammatory Drugs	- **Vitamin E:** Benefits in non-diabetic FLD patients - **Pentoxifylline:** Anti-inflammatory properties, reduces liver inflammation and fibrosis
Surgical Interventions	Bariatric Surgery	- **Types of Procedures:** Gastric bypass, sleeve gastrectomy, adjustable gastric banding - **Effects on FLD:** Significant weight loss, improvements in liver steatosis, inflammation, and fibrosis

	Liver Transplantation	- **Indications:** For end-stage liver disease due to FLD - **Outcomes:** Favorable post-transplant outcomes, risk of recurrence if underlying factors persist
Emerging Therapies	Gene Therapy	- **Approach:** Targets specific genetic mutations or pathways - **Current Status:** Experimental stage with ongoing trials
	Stem Cell Therapy	- **Approach:** Uses stem cells to repair damaged liver tissue - **Current Status:** Early-stage research with promising preliminary results

Table 4 *(Challenges, Limitations, and Future Directions in Fatty Liver Disease.)*

Category	Subcategory	Details
Challenges	Limitations of Current Treatments	- **Effectiveness:** Variable response to lifestyle modifications and pharmacological treatments - **Side Effects:** Adverse effects associated with some medications (e.g., thiazolidinediones)
	Diagnostic Challenges	- **Non-Invasive Tests:** Limited sensitivity and specificity of imaging and biomarkers - **Invasive Procedures:** Risks associated with liver biopsy, sampling variability
	Patient Compliance	- **Adherence:** Difficulty in maintaining long-term lifestyle changes and medication adherence - **Awareness:** Lack of patient awareness and understanding of FLD
	Research Gaps	- **Pathogenesis:** Incomplete understanding of the molecular mechanisms driving FLD - **Long-Term Outcomes:** Limited data on the long-term effectiveness and safety of emerging therapies
Limitations	Current Therapeutic Approaches	- **Lifestyle Modifications:** Often challenging for patients to implement and maintain - **Pharmacological Treatments:** Limited options with mixed effectiveness and potential side effects
	Diagnostic Methods	- **Imaging Techniques:** May not detect early-stage disease or mild steatosis - **Biomarkers:** Need for more specific and reliable markers for FLD diagnosis and progression
	Surgical Interventions	- **Invasiveness:** Associated risks such as infection, bleeding, and anesthesia complications - **Accessibility:** High costs and limited availability for some patients
Future Directions	Improved Diagnostic Techniques	- **Advanced Imaging:** Development of more accurate and less invasive imaging modalities

		- **Biomarkers:** Identification of new biomarkers for early detection and monitoring of FLD
	Personalized Medicine	- **Genetic Profiling:** Use of genetic information to tailor treatments to individual patients - **Precision Therapies:** Development of targeted therapies based on specific molecular pathways
	Novel Therapeutic Approaches	- **Gene Therapy:** Exploration of gene editing techniques to correct genetic mutations - **Stem Cell Therapy:** Further research into the use of stem cells for liver regeneration
	Prevention Strategies	- **Public Health Initiatives:** Programs to raise awareness about FLD and promote healthy lifestyles - **Policy Changes:** Implementation of policies to reduce the consumption of unhealthy foods and beverages

CONCLUSION

Fatty liver disease (FLD) is a significant global health issue driven by obesity, diabetes, and sedentary lifestyles. Its pathogenesis involves complex interactions among genetic, metabolic, inflammatory, and environmental factors. While current diagnostic methods and treatments, including lifestyle changes, medications, and surgical options, offer some benefits, they also have limitations and challenges. Emerging therapies like gene and stem cell therapy show promise but require further research. Addressing FLD effectively will require advancements in diagnostics, personalized treatments, and comprehensive prevention strategies to improve patient outcomes and reduce the disease's global impact.

REFERENCES

1. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.
2. Sharma B, John S. Nonalcoholic steatohepatitis (NASH). 2017.
3. Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health. 2021;18(10).
4. Parameswaran M, Hasan HA, Sadeque J, Jhaveri S, Avanthika C, Arisoyin AE, et al. Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). Cureus. 2021;13(12):e20776.
5. Fujiwara Y, Eguchi S, Murayama H, Takahashi Y, Toda M, Imai K, et al. Relationship between diet/exercise and pharmacotherapy to enhance the GLP-1 levels in type 2 diabetes. Endocrinol Diabetes Metab. 2019;2(3):e00068.
6. Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, et al. The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities. Curr Obes Rep. 2023;12(4):453-73.
7. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-64.

8. Goyal NP, Rosenthal SB, Nasamran C, Behling CA, Angeles JE, Fishbein MH, et al. Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children. Hepatology. 2023;77(1):197-212.
9. Longo M, Meroni M, Paolini E, Erconi V, Carli F, Fortunato F, et al. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. Cell Mol Gastroenterol Hepatol. 2022;13(3):759-88.
10. Meroni M, Longo M, Tria G, Dongiovanni P. Genetics Is of the Essence to Face NAFLD. Biomedicines. 2021;9(10):1359.
11. Castillo-Leon E, Cioffi CE, Vos MB. Perspectives on youth-onset nonalcoholic fatty liver disease. Endocrinol Diabetes Metab. 2020;3(4):e00184.
12. Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep. 2021;3(3):100284.
13. Badmus OO, Hillhouse SA, Anderson CD, Hinds TD, Stec DE. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clin Sci (Lond). 2022;136(18):1347-66.
14. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018;98(4):2133-223.
15. Hardwick JP, Osei-Hyiaman D, Wiland H, Abdelmegeed MA, Song BJ. PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. PPAR Res. 2009;2009:952734.
16. Lodhi IJ, Wei X, Semenkovich CF. Lipoexpediency: de novo lipogenesis as a metabolic signal transmitter. Trends Endocrinol Metab. 2011;22(1):1-8.
17. Shi C, Zhu L, Chen X, Gu N, Chen L, Zhu L, et al. IL-6 and TNF-α induced obesity-related inflammatory response through transcriptional regulation of miR-146b. J Interferon Cytokine Res. 2014;34(5):342-8.
18. Cao S, Liu M, Sehrawat TS, Shah VH. Regulation and functional roles of chemokines in liver diseases. Nat Rev Gastroenterol Hepatol. 2021;18(9):630-47.
19. Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127(1):55-64.
20. Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol. 2020;26(2):109-33.
21. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, et al. Oxidative Stress: Harms and Benefits for Human Health. Oxid Med Cell Longev. 2017;2017:8416763.
22. Rybka J, Kupczyk D, Kędziora-Kornatowska K, Pawluk H, Czuczejko J, Szewczyk-Golec K, et al. Age-related changes in an antioxidant defense system in elderly patients with essential hypertension compared with healthy controls. Redox Rep. 2011;16(2):71-7.
23. Melo HM, Santos LE, Ferreira ST. Diet-Derived Fatty Acids, Brain Inflammation, and Mental Health. Front Neurosci. 2019;13:265.
24. Clemente-Suárez VJ, Beltrán-Velasco AI, Redondo-Flórez L, Martín-Rodríguez A, Tornero-Aguilera JF. Global Impacts of Western Diet and Its Effects on Metabolism and Health: A Narrative Review. Nutrients. 2023;15(12).
25. Choi JH, Sohn W, Cho YK. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26(4):662-9.
26. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082-90.
27. Pasanta D, Htun KT, Pan J, Tungjai M, Kaewjaeng S, Kim H, et al. Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications. Diagnostics (Basel). 2021;11(5).

28. Lee DH. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol. 2017;23(4):290-301.
29. 29. Lala V, Zubair M, Minter D. Liver function tests. StatPearls. 2023.
30. Zeng Y, He H, An Z. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease. Dis Markers. 2022;2022:1254014.
31. Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics (Basel). 2022;12(2).
32. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013;37(3):544-55.
33. Semmler G, Datz C, Trauner M. Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S244-s60.
34. Vidal-Cevallos P, Sorroza-Martínez AP, Chávez-Tapia NC, Uribe M, Montalvo-Javé EE, Nuño-Lámbarri N. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum. International Journal of Molecular Sciences. 2024;25(8):4397.
35. Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the management of type 2 diabetes. Cleve Clin J Med. 2017;84(7 Suppl 1):S15-s21.
36. Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. J Diabetes Complications. 2010;24(5):289-96.
37. Kim K, Ginsberg HN, Choi SH. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes Metab J. 2022;46(4):517-32.
38. Zhang CY, Liu S, Yang M. Antioxidant and anti-inflammatory agents in chronic liver diseases: Molecular mechanisms and therapy. World J Hepatol. 2023;15(2):180-200.
39. Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, et al. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. World J Hepatol. 2019;11(2):138-49.
40. 40. Russo FP, Ferrarese A, Zanetto A. Recent advances in understanding and managing liver transplantation. F1000Res. 2016;5.
41. Parambi DGT, Alharbi KS, Kumar R, Harilal S, Batiha GE, Cruz-Martins N, et al. Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. Mol Neurobiol. 2022;59(1):191-233.
42. Li TT, Wang ZR, Yao WQ, Linghu EQ, Wang FS, Shi L. Stem Cell Therapies for Chronic Liver Diseases: Progress and Challenges. Stem Cells Transl Med. 2022;11(9):900-11.